QurAlis

QurAlis is a private clinical-stage biotechnology company developing precision medicines for amyotrophic lateral sclerosis and other neurodegenerative and neurological diseases. The company combines genetically validated targets, human disease models, biomarkers, and its proprietary FlexASO antisense splice-modulation platform to build disease-modifying therapies. Its lead programs include QRL-201, an antisense oligonucleotide intended to restore STMN2 expression in ALS, and QRL-101, a selective Kv7.2/7.3 ion channel opener being developed for ALS and epilepsy. QurAlis has also advanced UNC13A-targeting RNA therapies, including QRL-204, which was licensed to Eli Lilly in 2024. The company’s focus is centered on TDP-43-related biology and related RNA mis-splicing mechanisms across ALS, FTD, and additional CNS disorders.